for weight loss on its platform with introductory pricing starting at $49 for the first month.
Thursday, February 5, 2026
Qualcomm, Arm Hit by Concern That Memory Shortage Is Spreading
Shares of Qualcomm Inc. and Arm Holdings Plc fell steeply after the semiconductor companies delivered quarterly reports, hurt by concern that a shortage of memory chips will crimp growth in the electronics industry.
Both stocks declined more than 8% in extended trading late Wednesday after management signaled that memory constraints will limit phone production. Qualcomm is the largest maker of processors that run smartphones, and Arm gets much of its revenue from royalties on technology used by that industry.
LB Pharmaceuticals stock rises on $100M financing
LB Pharmaceuticals announces a $100 million private placement of common stock and pre-funded warrants with institutional investors to fund a Phase 2 trial of LB-102 in major depressive disorder and for general corporate purposes.
NovoCure Faces CMS Billing Revocation, Revenue Impact Uncertain
Novocure Inc. disclosed that CMS had revoked its billing privileges for the company’s products, retroactive to December 17, 2025, due to an administrative issue with its triannual re-validation rather than any substantive failure to qualify. While Novocure has submitted a Corrective Action Plan and continues to treat existing and new patients, it cannot bill Medicare, Medicare Advantage and other CMS-related payors during the revocation period and estimates that it will be unable to recognize roughly $13 million in monthly revenue from these payors until billing privileges are restored, with the timing, ultimate resolution and extent of recoverable revenue for services rendered in the interim remaining uncertain.
Cardinal Health posts strong Q2 results, raises guidance
Cardinal Health reported strong second-quarter fiscal 2026 results, with revenue rising 19% year over year to $65.6 billion, GAAP operating earnings up 29% to $707 million and non-GAAP operating earnings up 38% to $877 million, driving a 36% increase in non-GAAP diluted EPS to $2.63. The Pharmaceutical and Specialty Solutions segment remained the main growth engine, with revenue up 19% to $60.7 billion and segment profit up 29% to $687 million, supported by brand and specialty drug sales, acquisitions of MSO platforms and positive generics performance, while the Global Medical Products and Distribution segment delivered 3% revenue growth to $3.3 billion and a 106% jump in profit to $37 million on customer volume growth and cost optimization efforts.
TransCode submits IND amendment for colorectal cancer candidate
TransCode Therapeutics announces it has submitted an IND amendment to the FDA for a planned Phase 2a PRE-I-SPY clinical trial of its lead candidate TTX-MC138 in colorectal cancer.
AIM ImmunoTech reports positive year-end interim Phase 2 data
for Ampligen plus Imfinzi in metastatic pancreatic cancer, highlighting continued PFS/OS benefits, favorable safety, high quality of life and an updated corporate strategy presentation prioritizing Ampligen’s path toward Phase 3.
Subscribe to:
Posts (Atom)